Investments
19Portfolio Exits
4About BD Ventures
BD is a medical technology company that aims to serve healthcare institutions, life science researchers, clinical laboratories, industry, and the general public.BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.

Want to inform investors similar to BD Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing BD Ventures
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find BD Ventures in 1 Expert Collection, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Latest BD Ventures News
Oct 7, 2014
Bona Film Group Adds Donghui Pan to Its Board of Directors Mr. Rhodes is a veteran healthcare executive with extensive experience in the diagnostics and life science tools sectors. During his sixteen-year career at Becton, Dickinson and Co., Mr. Rhodes held several senior leadership positions, and was most recently an Executive Officer and BD's SVP of Corporate Strategy and Development; immediately prior to this, he was Worldwide President of BD Biosciences, a $1.4B business unit that was comprised of Cell Analysis, Discovery Labware, and Advanced Bioprocessing. Mr. Rhodes was also responsible for creating BD Ventures, the venture capital arm of BD, which has invested in numerous high-tech healthcare start-ups. Prior to BD, Mr. Rhodes held senior business development positions at Johnson & Johnson and Pfizer. “Bill brings a wealth of knowledge and experience to Paramit and will be a tremendous asset as we continue to collaborate with our customers around the world to develop and manufacture medical devices and life science instruments that positively impact patient care. Bill will help us further expand our presence in life science instruments and we are excited to have him on our board,” said Billoo Rataul , Paramit’s chief executive officer. Mr. Rhodes is a member of and a Senior Executive in Residence for Cornell University’s McGovern Family Life Sciences Center Advisory Council, as well as Clinical Instructor at Weill Cornell Medical College. He serves or has served on the boards of Omega Diagnostics plc, Andor Technologies plc, VitaGen Inc., Novocell Inc., the California Healthcare Institute, BIO, the Silicon Valley Leadership Group and the San Jose State University Research Foundation. Mr. Rhodes holds a Bachelor of Science from Cornell University and a Masters in International Business from Seton Hall University, where he received the business school's Leadership Award and taught corporate mergers and acquisitions as an adjunct professor. “I am honored to join the Paramit board and work with this exceptional team,” Rhodes said. “Paramit is a world-class global company providing many of the most innovative and fastest growing companies in the healthcare industry with high quality and high value manufacturing services for complex medical devices and life science instruments. Paramit’s ability to provide zero defect mechanical assembly of complex instruments via the vPoke system is unique in this industry and I look forward to helping them with future direction and continued growth.” About Paramit Headquartered in Morgan Hill, CA, Paramit Corporation is a leading global manufacturer of complex medical devices and life science instruments for many of the most innovative and fastest growing companies in the healthcare industry. The company provides zero defect mechanical assembly via a patent pending computer directed assembly process called vPoke and has expertise in mechatronics, fluidics, optics, RF and printed circuit board assembly. Paramit has long-term partnerships with market leading customers, whom it services through its FDA-registered and ISO13485 certified facilities. For more information, please visit www.paramit.com . Paramit Corporation
BD Ventures Investments
19 Investments
BD Ventures has made 19 investments. Their latest investment was in Sonavex as part of their Series A - III on November 11, 2019.

BD Ventures Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
11/1/2019 | Series A - III | Sonavex | $1.8M | Yes | 1 | |
4/11/2011 | Unattributed VC - III | Cellerant Therapeutics | $2.02M | No | ||
9/13/2010 | Debt - II | CoImmune | $4.85M | No | AAC Capital Partners, Aurora Funds, BD Ventures, CDP Capital, Cordova Ventures, Forbion, GeneChem Therapeutics Venture Fund, Harbinger/Aurora Venture Fund, InterSouth Partners, Japan Asia Investment Group, Kirin Pharma Company, Lumira Ventures, Mizuho Capital, Morningside Ventures, Oakwood Medical Investors, Pacific Horizon Ventures, Sanders Morris Harris Private Equity, Senmed Medical Ventures, Signet Healthcare Partners, Sutter Hill Ventures, TFG Capital Unternehmensbeteiligungsgesellschaft, TVM Capital Life Science, and Vestcorp AG | |
6/7/2010 | Unattributed VC - II | |||||
10/8/2009 | Series C |
Date | 11/1/2019 | 4/11/2011 | 9/13/2010 | 6/7/2010 | 10/8/2009 |
---|---|---|---|---|---|
Round | Series A - III | Unattributed VC - III | Debt - II | Unattributed VC - II | Series C |
Company | Sonavex | Cellerant Therapeutics | CoImmune | ||
Amount | $1.8M | $2.02M | $4.85M | ||
New? | Yes | No | No | ||
Co-Investors | AAC Capital Partners, Aurora Funds, BD Ventures, CDP Capital, Cordova Ventures, Forbion, GeneChem Therapeutics Venture Fund, Harbinger/Aurora Venture Fund, InterSouth Partners, Japan Asia Investment Group, Kirin Pharma Company, Lumira Ventures, Mizuho Capital, Morningside Ventures, Oakwood Medical Investors, Pacific Horizon Ventures, Sanders Morris Harris Private Equity, Senmed Medical Ventures, Signet Healthcare Partners, Sutter Hill Ventures, TFG Capital Unternehmensbeteiligungsgesellschaft, TVM Capital Life Science, and Vestcorp AG | ||||
Sources | 1 |
BD Ventures Portfolio Exits
4 Portfolio Exits
BD Ventures has 4 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/11/2022 | Acquired | 9 | |||
Date | 7/11/2022 | |||
---|---|---|---|---|
Exit | Acquired | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 9 |
BD Ventures Team
1 Team Member
BD Ventures has 1 team member, including former Founder, Ohad Bendror.
Name | Work History | Title | Status |
---|---|---|---|
Ohad Bendror | Founder | Former |
Name | Ohad Bendror |
---|---|
Work History | |
Title | Founder |
Status | Former |